What is AMGN's current stock price?

As of now, AMGN is trading at $341.88, with a daily change of -0.31%.

What are the risks associated with AMGN stock?

AMGN has Low, risk level based on volatility, sector strength, volume, investor confidence and outlook.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

AMGN Stock Analysis & IQ Rating | Amgen

AMGN

Amgen

$341.88

-$1.06 | -0.31%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$353.25

MKT CAP

$184.10B

52W Low

$261.43

VOL

$2.29M

P/E Ratio

26.43

AVG VOL

$2.81M

RSI

56.77

TREND

Uptrend

AMGN Stock IQ

Login to see Amgen (AMGN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

AMGN Target Price

Login to display

Strengths

AMGN Rewards

Earnings are forecast to grow

AMGN Rewards

Upgraded on attractively valued

AMGN Rewards

Trading below its fair value

AMGN Rewards

Outperform the market

AMGN Price Performance

$320.72 (+6.60%)

$318.66 (+7.29%)

$279.97 (+22.11%)

$292.8 (+16.76%)

1year

6month

3month

1month

AMGN Analysts Opinion

Overall standing based on market and analyst consensus. menu Hover over the category for more information

AMGN Analysts Opinion

AMGN Analysts opinion is negative and it remained unchanged from the past 3 months

AMGN Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

68%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

50%

100%

AMGN Street Sentiment

AMGN Street Sentiment is bullish and have positive views on the near-term outlook

AMGN Risk Level

AMGN has Low risk level

Low

LOW

HIGH

AMGN Performance Sentiment

Sentiments overview associated with events and the stock performance

68%

29%

Positive

Negative

19 out of 28
events present

8 out of 28
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support
Price

$342.22

Resistance
Price

$320.72

Current Price Range

$351.32

Show methods +

Analyst Consensus

Recent Upgrades and Downgrades

86%

Buy

Hold

Sell

Consensus Rating

STRONG BUY

6

1

0

Date

Action

Rating

Firm

Jan 29, 2026

Price Target Raised

Buy

UBS

Jan 06, 2026

Upgrade

Buy

UBS

Dec 04, 2025

Reiterate

Outperform

BMO Capital

Dec 03, 2025

Reiterate

Buy

Goldman Sachs

Nov 14, 2025

Reiterate

Overweight

Piper Sandler

Linked to AMGN

Close Price

Change

MRNA

Moderna

44.07

-5.95%

BIIB

Biogen

179.89

+2.14%

EXEL

Exelixis

41.36

-2.18%

CRSP

CRISPR Therapeutics

49.96

-6.35%

CHRS

Coherus BioSciences

2.16

-7.30%

Recently Viewed

Close Price

Change

AMGN

Amgen

341.88

-0.31%

BKNG

Booking Holdings Inc

5001.84

-2.18%

CRML

Critical Metals Corp.

13.17

-6.00%

CVX

Chevron

176.90

+3.34%

GME

Gamestop

23.88

+4.69%

AMGN Latest Analysis +

Amgen ends collaboration agreement with Kyowa Kirin for eczema asset.

Fri Jan 30, 2026

$341.88 | -0.31%

Activity

Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends. ) terminated on Friday the current rocatinlimab development and commercialization collaboration.Kyowa Kirin will control of the global rocatinlimab program including regulatory filings and future commercialization.The business decision is the result of a strategic portfolio prioritization by Amgen.In June 2021 Amgen and Kyowa Kirin to jointly develop and commercialize KHK4083 a Phase 3-ready anti-OX40 f

Fri Jan 30, 2026

$341.88 | -0.31%

Activity

Amgen Kyowa Kirin End Collaboration On Atopic Dermatitis Drug Rocatinlimab . (RTTNews) - Kyowa Kirin Co. Ltd. (KYKOY) said on Friday it has ended its development and commercialization partnership with Amgen for rocatinlimab with the Japanese drugmaker regaining full control of the drugs development. The decision follows a strategic portfolio review by

Fri Jan 30, 2026

$341.88 | -0.31%

Activity

Countdown to Amgen (AMGN) Q4 Earnings: Wall Street Forecasts for Key Metrics. Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended December 2025 by going beyond Wall Streets top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Thu Jan 29, 2026

$342.94 | +0.21%

Earnings

Amgen (AMGN) is a Top-Ranked Value Stock: Should You Buy?. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Thu Jan 29, 2026

$342.94 | +0.21%

Potential

UBS Raises Amgen (AMGN) Target as Pharma and Biotech Setup Improves. Amgen Inc. (NASDAQ:AMGN) is included among the 12 Best Dow Jones Dividend Stocks to Buy According to Hedge Funds. On January 26 UBS lifted its price target on Amgen Inc. (NASDAQ:AMGN) to $390 from $380 and kept a Buy rating on the stock. The call reflects a more constructive view on the broader US pharma [….]

Thu Jan 29, 2026

$342.94 | +0.21%

Activity

Rating

Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for. Amgen (AMGN) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tue Jan 27, 2026

$351.32 | +0.47%

Earnings

Bernstein Calls 2026 a Waiting Year for Amgens (AMGN) MariTide. Amgen Inc. (NASDAQ:AMGN) is included among the 15 Best S&.P 500 Dividend Stocks to Buy in 2026. On January 20 Bernstein downgraded Amgen Inc. (NASDAQ:AMGN) to Market Perform from Outperform while leaving its $335 price target unchanged. The firm said the decision was mainly driven by its view that 2026 is a waiting year for [….]

Tue Jan 27, 2026

$351.32 | +0.47%

Potential

Amgen (AMGN) Laps the Stock Market: Heres Why. In the most recent trading session Amgen (AMGN) closed at $349.69 indicating a 1.43% shift from the previous trading day.

Mon Jan 26, 2026

$349.69 | +1.43%

Momentum

Heres Why Amgen (AMGN) is a Strong Momentum Stock. Whether youre a value growth or momentum investor finding strong stocks becomes easier with the Zacks Style Scores a top feature of the Zacks Premium research service.

Mon Jan 26, 2026

$349.69 | +1.43%

Momentum

FAQ About AMGN Stock Insights

What is AMGN current stock price?

What are AMGN stock strengths?

What is AMGN Risk Level?

What is AMGN market cap and volume?

What is AMGN current Stock IQ?

Should I buy AMGN stock right now?

Is AMGN a Strong Buy right now?

What does a 'Strong Buy' rating mean for AMGN?

What does a 'Strong Sell' rating mean for AMGN?

What factors influence AMGN's Stock IQ?

Explore our AMGN Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored AMGN Stock Strategies
Effective Risk Management

FIND US ON

Receive our AMGN Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

AMGN

Amgen

Set Alerts

Current Price

$341.88

-$1.06 | -0.31%

52W High

$353.25

MKT CAP

$184.10B

52W Low

$261.43

VOL

$2.29M

P/E Ratio

26.43

AVG VOL

$2.81M

RSI

56.77

TREND

Uptrend

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Linked to AMGN

Symbol

Close

Change

MRNA

Moderna

44.07

-5.95%

BIIB

Biogen

179.89

+2.14%

EXEL

Exelixis

41.36

-2.18%

CRSP

CRISPR Therapeutics

49.96

-6.35%

CHRS

Coherus BioSciences

2.16

-7.30%

AMGN Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

68%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

50%

100%

AMGN Street Sentiment

AMGN Street Sentiment is bullish and have positive views on the near-term outlook

AMGN Risk Level

AMGN has Low risk level

Low

LOW

HIGH

AMGN Performance Sentiment

Sentiments overview associated with events and the stock performance.

68%

29%

Positive

Negative

19 out of 28
events present

8 out of 28
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support
Price

$342.22

Resistance
Price

$320.72

Current Price Range

$351.32

Show methods +

Latest Analyst Actions

Overall Wall Street Rating

86%

Buy

Hold

Sell

Consensus Rating

STRONG BUY

6

1

0

Date

Action

Rating

Firm

Jan 29, 2026

Price Target Raised

Buy

UBS

Jan 06, 2026

Upgrade

Buy

UBS

Dec 04, 2025

Reiterate

Outperform

BMO Capital

Dec 03, 2025

Reiterate

Buy

Goldman Sachs

Nov 14, 2025

Reiterate

Overweight

Piper Sandler

AMGN Stock IQ

Login to unlock Amgen (AMGN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Target Price

Login to display

Stock Insights

Strengths

AMGN Rewards

Earnings are forecast to grow

AMGN Rewards

Upgraded on attractively valued

AMGN Rewards

Trading below its fair value

AMGN Rewards

Outperform the market

AMGN Latest Analysis

Amgen ends collaboration agreement with Kyowa Kirin for eczema asset.

Fri Jan 30, 2026

$341.88 | -0.31%

Activity

Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends. ) terminated on Friday the current rocatinlimab development and commercialization collaboration.Kyowa Kirin will control of the global rocatinlimab program including regulatory filings and future commercialization.The business decision is the result of a strategic portfolio prioritization by Amgen.In June 2021 Amgen and Kyowa Kirin to jointly develop and commercialize KHK4083 a Phase 3-ready anti-OX40 f

Fri Jan 30, 2026

$341.88 | -0.31%

Activity

Amgen Kyowa Kirin End Collaboration On Atopic Dermatitis Drug Rocatinlimab . (RTTNews) - Kyowa Kirin Co. Ltd. (KYKOY) said on Friday it has ended its development and commercialization partnership with Amgen for rocatinlimab with the Japanese drugmaker regaining full control of the drugs development. The decision follows a strategic portfolio review by

Fri Jan 30, 2026

$341.88 | -0.31%

Activity

Countdown to Amgen (AMGN) Q4 Earnings: Wall Street Forecasts for Key Metrics. Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended December 2025 by going beyond Wall Streets top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Thu Jan 29, 2026

$342.94 | +0.21%

Earnings

Amgen (AMGN) is a Top-Ranked Value Stock: Should You Buy?. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Thu Jan 29, 2026

$342.94 | +0.21%

Potential

UBS Raises Amgen (AMGN) Target as Pharma and Biotech Setup Improves. Amgen Inc. (NASDAQ:AMGN) is included among the 12 Best Dow Jones Dividend Stocks to Buy According to Hedge Funds. On January 26 UBS lifted its price target on Amgen Inc. (NASDAQ:AMGN) to $390 from $380 and kept a Buy rating on the stock. The call reflects a more constructive view on the broader US pharma [….]

Thu Jan 29, 2026

$342.94 | +0.21%

Activity

Rating

Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for. Amgen (AMGN) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tue Jan 27, 2026

$351.32 | +0.47%

Earnings

Bernstein Calls 2026 a Waiting Year for Amgens (AMGN) MariTide. Amgen Inc. (NASDAQ:AMGN) is included among the 15 Best S&.P 500 Dividend Stocks to Buy in 2026. On January 20 Bernstein downgraded Amgen Inc. (NASDAQ:AMGN) to Market Perform from Outperform while leaving its $335 price target unchanged. The firm said the decision was mainly driven by its view that 2026 is a waiting year for [….]

Tue Jan 27, 2026

$351.32 | +0.47%

Potential

Amgen (AMGN) Laps the Stock Market: Heres Why. In the most recent trading session Amgen (AMGN) closed at $349.69 indicating a 1.43% shift from the previous trading day.

Mon Jan 26, 2026

$349.69 | +1.43%

Momentum

Heres Why Amgen (AMGN) is a Strong Momentum Stock. Whether youre a value growth or momentum investor finding strong stocks becomes easier with the Zacks Style Scores a top feature of the Zacks Premium research service.

Mon Jan 26, 2026

$349.69 | +1.43%

Momentum

Discover AMGN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of AMGN. We're here to help you make informed investment decisions today.

FIND US ON

Receive our AMGN Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

AMGN Stock trends

AMGN Stock performance

AMGN Stock analysis

AMGN investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing AMGN

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing AMGN

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

AMGN Stock Analysis & IQ Rating | Amgen

AMGN Stock IQ

AMGN Target Price

AMGN Analysts Opinion

AMGN Street Sentiment

AMGN Risk Level

AMGN Performance Sentiment

Key Price Levels

Analyst Consensus

Explore our AMGN Stock insights

Receive our AMGN Daily Alerts

AMGN Street Sentiment

AMGN Risk Level

Key Price Levels

Latest Analyst Actions

Discover AMGN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of AMGN. We're here to help you make informed investment decisions today.

Receive our AMGN Daily Alerts

AMGN Alerts